Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells

Leukemia

Volumn 24, Issue 4, 2010, Pages 756-764

  Pellagatti, A ^a   Cazzola, M ^b   Giagounidis, A ^c   Perry, J ^a   Malcovati, L ^b   Della Porta, M G ^b   Jadersten M ^d   Killick, S ^e   Verma, A ^f   Norbury, C J ^g   Hellstrom Lindberg E ^d   Wainscoat, J S ^a   Boultwood, J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PAVIA   (Italy)

^c ST JOHANNES HOSPITAL   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Gene expression pathways; Gene expression profiling; Hematopoietic stem cells; Myelodysplastic syndromes

Indexed keywords

CD24 ANTIGEN; CHEMOKINE; DNA; GENE PRODUCT; GRAVIN; INTEGRIN; INTERFERON; LYMPHOID ENHANCER FACTOR 1; PROTEIN ARPP 21; PROTEIN DLK1; PROTEIN IFI44L; PROTEIN IFIT1; PROTEIN IFIT3; PROTEIN IFITM1; PROTEIN IMP3; PROTEIN PTHR2; THROMBOPOIETIN; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; CD34 SELECTION; CELL CYCLE REGULATION; CELL SURVIVAL; CHROMOSOME 5Q; CHROMOSOME 7Q; CHROMOSOME DELETION; CONTROLLED STUDY; DNA DAMAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRISOMY 8;

EID: 77950943405     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.31     Document Type: Article

References (69)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999, 340, 1649-1660.
2. Greenberg PL, Young NS, Gattermann N. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program 2002, 136-161.
3. Komrokji RS, Bennett JM. Evolving classifications of the myelo-dysplastic syndromes. Curr Opin Hematol 2007; 14: 98-105.
4. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003; 27: 95-120.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
6. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
7. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419-1432.
8. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelodys-plastic syndromes. Blood 1997; 89: 2079-2088.
9. Sanz GF, Sanz MA, Greenberg PL. Prognostic factors and scoring systems in myelodysplastic syndromes. Haematologica 1998; 83: 358-368.
10. Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol 2001; 14: 479-495.
11. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no.5 chromosome. Nature 1974; 251: 437-438.
12. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994; 84: 3253-3260.
13. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q-syndrome. Hematology 2004; 9: 271-277.
14. Maciejewski JP, Risitano A, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood 2002; 99: 3129-3135.
15. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clin Proc 2005; 80: 681-698.
16. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
17. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
18. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223-232.
19. Jadersten M, Hellstrom-Lindberg E. Myelodysplastic syndromes: biology and treatment. J Intern Med 2009; 265: 307-328.
20. Boehrer S, Ades L, Tajeddine N, Hofmann WK, Kriener S, Bug G et al. Suppression of the DNA damage response in acute myeloid leukemia versus myelodysplastic syndrome. Oncogene 2009; 28: 2205-2218.
21. Network CGAR. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
22. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
23. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
24. Edgar R, Domrachev M, Lash AE. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 2002; 30: 207-210.
25. Kitagawa M, Saito I, Kuwata T, Yoshida S, Yamaguchi S, Takahashi M et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997; 11: 2049-2054.
26. Felli N, Pedini F, Zeuner A, Petrucci E, Testa U, Conticello C et al. Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol 2005; 175: 1464-1472.
27. Yang L, Dybedal I, Bryder D, Nilsson L, Sitnicka E, Sasaki Y et al. IFN-gamma negatively modulates self-renewal of repopulating human hemopoietic stem cells. J Immunol 2005; 174: 752-757.
28. Pellagatti A, Cazzola M, Giagounidis AA, Malcovati L, Porta MG, Killick S et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 2006; 108: 337-345.
29. Hofmann WK, Kalina U, Wagner S, Seipelt G, Ries C, Hoelzer D et al. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Exp Hematol 1999; 27: 395-400.
30. Kaushansky K, Broudy VC, Lin N, Jorgensen MJ, McCarty J, Fox N et al. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci USA 1995; 92: 3234-3238.
31. Yamazaki S, Nakauchi H. Insights into signaling and function of hematopoietic stem cells at the single-cell level. Curr Opin Hematol 2009; 16: 255-258.
32. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R et al. Dysregulated gene expression networks in human acute myelo-genous leukemia stem cells. Proc Natl Acad Sci USA 2009; 106: 3396-3401.
33. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004; 351: 657-667.
34. Bellini O, Casazza AM, di Marco A. Histological and histochemical studies of myocardial lesions in BALBc/Cr mice. Lab Anim Sci 1976; 26: 329-333.
35. Kotsianidis I, Bouchliou I, Nakou E, Spanoudakis E, Margaritis D, Christophoridou AV et al. Kinetics, function and bone marrow trafficking of CD4+CD25+FOXP3+ regulatory T cells in myelo-dysplastic syndromes (MDS). Leukemia 2009; 23: 510-518.
36. Sloand EM, Rezvani K. The role of the immune system in myelodysplasia: implications for therapy. Semin Hematol 2008; 45: 39-48.
37. Sternberg A, Killick S, Littlewood T, Hatton C, Peniket A, Seidl T et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. Blood 2005; 106: 2982-2991.
38. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88: 4275-4287.
39. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 3932-3938.
40. Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom AM et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood 2005; 106: 247-253.
41. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
42. Ko MA, Rosario CO, Hudson JW, Kulkarni S, Pollett A, Dennis JW et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 2005; 37: 883-888.
43. Lam MH, Liu Q, Elledge SJ, Rosen JM. Chk1 is haploinsufficient for multiple functions critical to tumor suppression. Cancer Cell 2004; 6: 45-59.
44. Zhao H, Watkins JL, Piwnica-Worms H. Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints. Proc Natl Acad Sci USA 2002; 99: 14795-14800.
45. West SC. Molecular views of recombination proteins and their control. Nat Rev Mol Cell Biol 2003; 4: 435-445.
46. Bindra RS, Glazer PM. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 2007; 26: 2048-2057.
47. Garuti G, Genazzani AR. Human neu oncogene is expressed in endometrial but not in ovarian adenocarcinomas. Cancer 1991; 67: 1713.
48. Tischkowitz M, Dokal I. Fanconi anaemia and leukaemiaFclinical and molecular aspects. Br J Haematol 2004; 126: 176-191.
49. Potapova O, Basu S, Mercola D, Holbrook NJ. Protective role for c-Jun in the cellular response to DNA damage. J Biol Chem 2001; 276: 28546-28553.
50. Kinjo K, Sandoval S, Sakamoto KM, Shankar DB. The role of CREB as a proto-oncogene in hematopoiesis. Cell Cycle 2005; 4: 1134-1135.
51. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
52. Montecucco C, Riccardi A, Traversi E, Giordano P, Mazzini G, Ascari E. Proliferative activity of bone marrow cells in primary dysmyelopoietic (preleukemic) syndromes. Cancer 1983; 52: 1190-1195.
53. Varma N, Varma S. Proliferative indices, cytogenetics, immuno-phenotye and other prognostic parameters in myelodysplastic syndromes. Indian J Pathol Microbiol 2008; 51: 97-101.
54. Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki C, Katrinakis G, Tsirakis G et al. Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. J Mol Histol 2004; 35: 857-863.
55. Fenaux P. Chromosome and molecular abnormalities in myelo-dysplastic syndromes. Int J Hematol 2001; 73: 429-437.
56. Mufti GJ. Pathobiology, classification, and diagnosis of myelodys-plastic syndrome. Best Pract Res Clin Haematol 2004; 17: 543-557.
57. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; 110: 4385-4395.
58. Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S et al. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood 2004; 104: 4210-4218.
59. Sloand EM, Kim S, Fuhrer M, Risitano AM, Nakamura R, Maciejewski JP et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002; 100: 4427-4432.
60. Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 1997; 11: 839-845.
61. Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L et al. Gene expression profiling of CD34+ cells in patients with the 5q-syndrome. Br J Haematol 2007; 139: 578-589.
62. Pellagatti A, Hellstrom-Lindberg E, Giagounidis A, Perry J, Malcovati L, Della Porta MG et al. Haploinsufficiency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal-and translation-related genes. Br J Haematol 2008; 142: 57-64.
63. Weston CR, Davis RJ. The JNK signal transduction pathway. Curr Opin Cell Biol 2007; 19: 142-149.
64. Carpinteiro A, Dumitru C, Schenck M, Gulbins E. Ceramide-induced cell death in malignant cells. Cancer Lett 2008; 264: 1-10.
65. Hutchinson J, Jin J, Cardiff RD, Woodgett JR, Muller WJ. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001; 21: 2203-2212.
66. Tanaka T, De Luca LM. Therapeutic potential of 'rexinoids' in cancer prevention and treatment. Cancer Res 2009; 69: 4945-4947.
67. Dominguez I, Sonenshein GE, Seldin DC. Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer. Cell Mol Life Sci 2009; 66: 1850-1857.
68. Graham SM, Cox AD, Drivas G, Rush MG, D'Eustachio P, Der CJ. Aberrant function of the Ras-related protein TC21/R-Ras2 triggers malignant transformation. Mol Cell Biol 1994; 14: 4108-4115.
69. Clark GJ, Kinch MS, Gilmer TM, Burridge K, Der CJ. Over-expression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 1996; 12: 169-176.